VAMSI KRISHNA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology
- Where
- KYLE, TX
- NPI
- 1891930863
- Received
- $1,973,918 in 3,229 records, 2019 to 2025 ($1,963,531 general, $10,387 research)
- As principal investigator
- $189,324 of research payments to others in 66 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 432 | $262,847 |
| 2024 | General payment | 482 | $346,118 |
| 2023 | General payment | 458 | $262,311 |
| 2022 | General payment | 470 | $275,353 |
| 2021 | General payment | 544 | $326,014 |
| 2021 | Research payment | 1 | $10,387 |
| 2020 | General payment | 357 | $252,795 |
| 2019 | General payment | 485 | $238,091 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 349 | $907,008 |
| Consulting Fee | 206 | $455,277 |
| Compensation for serving as faculty or as a speaker for a medical education program | 77 | $315,830 |
| Travel and Lodging | 390 | $149,030 |
| Food and Beverage | 2,178 | $93,159 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 17 | $27,345 |
| Honoraria | 5 | $15,750 |
| Research payment | 1 | $10,387 |
| Education | 6 | $130 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Shockwave Medical, Inc | $3,000 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-19 | Shockwave Medical, Inc | $3,000 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-19 | Kestra Medical Technology Services, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-18 | Mannkind Corporation | $14 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-12-17 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-12-17 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-16 | Kestra Medical Technology Services, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-15 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-12-15 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-12-15 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-12-13 | Reflow Medical Inc | $35 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | Shockwave Medical, Inc | $88 | Food and Beverage | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-11 | Shockwave Medical, Inc | $3,000 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-11 | Shockwave Medical, Inc | $3,000 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-11 | Shockwave Medical, Inc | $1,500 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-11 | Shockwave Medical, Inc | $750 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-10 | Stryker Corporation | $15 | Food and Beverage | In-kind items and services | ARTIX MT Device, INARI MEDICAL | 2025 | |
| 2025-12-10 | E.R. Squibb & Sons, L.L.C. | $10 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-09 | Abbott Laboratories | $131 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-12-09 | Shockwave Medical, Inc | $125 | Food and Beverage | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-12-09 | Abbott Laboratories | $107 | Food and Beverage | In-kind items and services | OPTIS Device, Structural Heart | 2025 | |
| 2025-12-07 | Teleflex LLC | $34 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-04 | Reflow Medical Inc | $11 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $9 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-03 | Abbott Laboratories | $1,200 | Travel and Lodging | In-kind items and services | COROFLOW Device, Vascular | 2025 | |
| 2025-12-03 | Teleflex LLC | $88 | Food and Beverage | In-kind items and services | PANTERA LEO Device, VASCULAR ACCESS | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-12-03 | Teleflex LLC | $4 | Food and Beverage | In-kind items and services | PANTERA LEO Device, VASCULAR ACCESS | 2025 | |
| 2025-12-02 | scPharmaceuticals Inc. | $2,800 | Honoraria | Cash or cash equivalent | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-12-02 | scPharmaceuticals Inc. | $126 | Travel and Lodging | Cash or cash equivalent | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-12-02 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-27 | Abbott Laboratories | $125 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-11-27 | Abbott Laboratories | $123 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-11-27 | Abbott Laboratories | $34 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-11-27 | Abbott Laboratories | $31 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-11-27 | Abbott Laboratories | $4 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-11-21 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-20 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-20 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-20 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-11-18 | Shockwave Medical, Inc | $258 | Travel and Lodging | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-11-18 | Shockwave Medical, Inc | $169 | Food and Beverage | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-11-17 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-17 | Shockwave Medical, Inc | $145 | Food and Beverage | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-11-17 | Shockwave Medical, Inc | $47 | Travel and Lodging | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-11-17 | Shockwave Medical, Inc | $46 | Travel and Lodging | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-11-17 | Reflow Medical Inc | $7 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-14 | Reflow Medical Inc | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-14 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-13 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-13 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-13 | scPharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-11-13 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-12 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-11 | Lilly USA, LLC | $476 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-11 | Lilly USA, LLC | $92 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $3,532 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $597 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $124 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-06 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-04 | Bard Peripheral Vascular, Inc. | $86 | Food and Beverage | In-kind items and services | RotarexS 6 F x 135 cm Device, Vascular/Oncology | 2025 | |
| 2025-11-03 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-11-03 | Reflow Medical Inc | $329 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-31 | Shockwave Medical, Inc | $3,000 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $63 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $42 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $10 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $10 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-29 | HEARTFLOW, INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-10-29 | HEARTFLOW, INC. | $162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-10-28 | Teleflex LLC | $206 | Food and Beverage | In-kind items and services | MANTA Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-10-28 | Shockwave Medical, Inc | $50 | Food and Beverage | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-27 | Penumbra, Inc. | $75 | Food and Beverage | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | 2025 | |
| 2025-10-27 | Edwards Lifesciences Corporation | $39 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-26 | Shockwave Medical, Inc | $66 | Food and Beverage | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-26 | Shockwave Medical, Inc | $58 | Food and Beverage | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-24 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-23 | scPharmaceuticals Inc. | $123 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-10-23 | Abbott Laboratories | $43 | Food and Beverage | In-kind items and services | TACTICATH ABLATION CATHETER, SENSOR ENABLED Device, Structural Heart | 2025 | |
| 2025-10-23 | Bard Peripheral Vascular, Inc. | $42 | Food and Beverage | In-kind items and services | RotarexS 6 F x 135 cm Device, Vascular/Oncology | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $42 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $25 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $21 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $10 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $10 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-23 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-22 | Teleflex LLC | $79 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-10-22 | Philips North America LLC | $43 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-10-22 | Bard Peripheral Vascular, Inc. | $4 | Food and Beverage | In-kind items and services | RotarexS 6 F x 135 cm Device, Vascular/Oncology | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-20 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-20 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-17 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $3,532 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $455 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $99 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-16 | Bard Peripheral Vascular, Inc. | $87 | Food and Beverage | In-kind items and services | RotarexS 6 F x 135 cm Device, Vascular/Oncology | 2025 | |
| 2025-10-16 | Novo Nordisk Inc | $15 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-15 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-14 | Shockwave Medical, Inc | $177 | Food and Beverage | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-14 | Philips North America LLC | $59 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-10-13 | Shockwave Medical, Inc | $67 | Food and Beverage | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-10-10 | Stryker Corporation | $32 | Food and Beverage | In-kind items and services | REVCORE THROMBECTOMY CATHETER Device, INARI MEDICAL | 2025 | |
| 2025-10-10 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-09 | Teleflex LLC | $23 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-10-09 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-08 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-08 | Philips North America LLC | $58 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-10-07 | Novo Nordisk Inc | $834 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-07 | Lilly USA, LLC | $476 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-07 | Abbott Laboratories | $129 | Food and Beverage | In-kind items and services | COROFLOW Device, Vascular | 2025 | |
| 2025-10-07 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-10-06 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-06 | Philips North America LLC | $29 | Food and Beverage | Cash or cash equivalent | Coronary Other Device, Medical Device | 2025 | |
| 2025-10-03 | HEARTFLOW, INC. | $29 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2025 | |
| 2025-10-03 | Abbott Laboratories | $26 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-10-03 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-02 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-02 | Lilly USA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-02 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-10-02 | Abbott Laboratories | $32 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-10-01 | Bard Peripheral Vascular, Inc. | $4 | Food and Beverage | In-kind items and services | RotarexS 6 F x 135 cm Device, Vascular/Oncology | 2025 | |
| 2025-09-30 | Lilly USA, LLC | $571 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-26 | Philips North America LLC | $34 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-09-25 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-24 | Abbott Laboratories | $114 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-09-23 | Philips North America LLC | $38 | Food and Beverage | Cash or cash equivalent | Coronary Other Device, Medical Device | 2025 | |
| 2025-09-22 | Novo Nordisk Inc | $3,532 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-22 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-22 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-22 | Novo Nordisk Inc | $293 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-22 | Novo Nordisk Inc | $93 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-19 | Philips North America LLC | $60 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-09-19 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-19 | Abbott Laboratories | $13 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-18 | scPharmaceuticals Inc. | $2,800 | Honoraria | Cash or cash equivalent | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $476 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-18 | scPharmaceuticals Inc. | $92 | Travel and Lodging | Cash or cash equivalent | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-09-18 | Teleflex LLC | $57 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-09-16 | Lilly USA, LLC | $67 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-13 | Teleflex LLC | $80 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-09-13 | Teleflex LLC | $11 | Food and Beverage | In-kind items and services | ORSIRO MISSION Device, INTERVENTIONAL ACCESS | 2025 | |
| 2025-09-12 | Abbott Laboratories | $150 | Food and Beverage | In-kind items and services | PRESSUREWIRE Device, Structural Heart | 2025 | |
| 2025-09-12 | Abbott Laboratories | $60 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-09-12 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-11 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-10 | Shockwave Medical, Inc | $750 | Consulting Fee | Cash or cash equivalent | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-09-09 | Abbott Laboratories | $1,200 | Travel and Lodging | In-kind items and services | COROFLOW Device, Vascular | 2025 | |
| 2025-09-09 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-05 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-04 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-09-04 | scPharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-09-04 | Cook Medical LLC | $3 | Food and Beverage | Cash or cash equivalent | ROSEN Device, Peripheral Intervention | 2025 | |
| 2025-09-02 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-29 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-29 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-29 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-28 | Novo Nordisk Inc | $8,046 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-28 | Novo Nordisk Inc | $1,467 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-28 | Novo Nordisk Inc | $456 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-28 | Novo Nordisk Inc | $415 | Travel and Lodging | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-28 | Novo Nordisk Inc | $119 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-27 | Lilly USA, LLC | $125 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-26 | Abbott Laboratories | $517 | Travel and Lodging | In-kind items and services | COROFLOW Device, Vascular | 2025 | |
| 2025-08-26 | Abbott Laboratories | $332 | Travel and Lodging | In-kind items and services | COROFLOW Device, Vascular | 2025 | |
| 2025-08-26 | Philips North America LLC | $45 | Food and Beverage | Cash or cash equivalent | IV Other Device, Medical Device | 2025 | |
| 2025-08-25 | Philips North America LLC | $36 | Food and Beverage | Cash or cash equivalent | Coronary Other Device, Medical Device | 2025 | |
| 2025-08-22 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-22 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-21 | scPharmaceuticals Inc. | $93 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-08-21 | Shockwave Medical, Inc | $77 | Food and Beverage | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Cardiology | 2025 | |
| 2025-08-21 | HEARTFLOW, INC. | $44 | Food and Beverage | Cash or cash equivalent | FFRct Device, Coronary | 2025 |
The latest 200 records of 3,229.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-23 | Medtronic, Inc. | Ascension Seton Medical Center | $2,620 | PSR-APV | 2025 |
| 2025-12-20 | BIOTRONIK INC. | Ascension Seton Medical Center | $477 | BIOFLOW-48 | 2025 |
| 2025-12-18 | BIOTRONIK INC. | Ascension Seton Medical Center | $3,138 | BIOFLOW-48 | 2025 |
| 2025-12-18 | BIOTRONIK INC. | Ascension Seton Medical Center | $1,387 | BIOFLOW-48 | 2025 |
| 2025-12-11 | Medtronic, Inc. | Ascension Seton Medical Center | $978 | PSR-APV | 2025 |
| 2025-11-26 | Medtronic, Inc. | Ascension Seton Medical Center | $640 | PSR-APV | 2025 |
| 2025-11-24 | Medtronic, Inc. | Ascension Seton Medical Center | $100 | PSR-APV | 2025 |
| 2025-11-24 | Medtronic, Inc. | Ascension Seton Medical Center | $40 | PSR-APV | 2025 |
| 2025-11-13 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $1,032 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-10-28 | Medtronic, Inc. | Ascension Seton Medical Center | $4,925 | PSR-APV | 2025 |
| 2025-10-09 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $547 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-09-24 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $62 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-09-19 | Medtronic, Inc. | Ascension Seton Medical Center | $20 | PSR-APV | 2025 |
| 2025-09-10 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $547 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-08-22 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $1,094 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-07-25 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $148 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-07-16 | Medtronic, Inc. | Ascension Seton Medical Center | $8,498 | PSR-APV | 2025 |
| 2025-06-26 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $2,757 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-05-05 | Medtronic, Inc. | Ascension Seton Medical Center | $1,250 | PSR-APV | 2025 |
| 2025-04-11 | Medtronic, Inc. | Ascension Seton Medical Center | $2,000 | PSR-APV | 2025 |
| 2025-03-07 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $531 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-02-14 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $5,442 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-02-07 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $1,250 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-01-30 | Medtronic, Inc. | Ascension Seton Medical Center | $4,609 | PSR-APV | 2025 |
| 2025-01-27 | Medtronic, Inc. | Ascension Seton Medical Center | $10,450 | PSR-APV | 2025 |
| 2025-01-24 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $62 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-01-22 | Janssen Research & Development, LLC | Ascension Seton Medical Center | $1,433 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2024-11-18 | Janssen Research & Development, LLC | ASCENSION SETON | $2,546 | 70033093ACS3003 | 2024 |
| 2024-11-06 | Janssen Research & Development, LLC | ASCENSION SETON | $62 | 70033093ACS3003 | 2024 |
| 2024-10-23 | Janssen Research & Development, LLC | ASCENSION SETON | $250 | 70033093ACS3003 | 2024 |
| 2024-10-18 | Janssen Research & Development, LLC | ASCENSION SETON | $5,828 | 70033093ACS3003 | 2024 |
| 2024-10-07 | Janssen Research & Development, LLC | ASCENSION SETON | $86 | 70033093ACS3003 | 2024 |
| 2024-10-02 | Janssen Research & Development, LLC | ASCENSION SETON | $31 | 70033093ACS3003 | 2024 |
| 2024-08-09 | Janssen Research & Development, LLC | ASCENSION SETON | $374 | 70033093ACS3003 | 2024 |
| 2024-07-24 | Janssen Research & Development, LLC | ASCENSION SETON | $1,933 | 70033093ACS3003 | 2024 |
| 2024-07-12 | Janssen Research & Development, LLC | ASCENSION SETON | $62 | 70033093ACS3003 | 2024 |
| 2024-06-19 | Janssen Research & Development, LLC | ASCENSION SETON | $31 | 70033093ACS3003 | 2024 |
| 2024-06-17 | Janssen Research & Development, LLC | ASCENSION SETON | $1,158 | 70033093ACS3003 | 2024 |
| 2024-06-07 | Janssen Research & Development, LLC | ASCENSION SETON | $86 | 70033093ACS3003 | 2024 |
| 2024-05-24 | Janssen Research & Development, LLC | ASCENSION SETON | $31 | 70033093ACS3003 | 2024 |
| 2024-04-26 | Janssen Research & Development, LLC | ASCENSION SETON | $1,368 | 70033093ACS3003 | 2024 |
| 2024-04-08 | Janssen Research & Development, LLC | ASCENSION SETON | $31 | 70033093ACS3003 | 2024 |
| 2024-03-22 | Janssen Research & Development, LLC | ASCENSION SETON | $1,433 | 70033093ACS3003 | 2024 |
| 2024-03-06 | Janssen Research & Development, LLC | ASCENSION SETON | $155 | 70033093ACS3003 | 2024 |
| 2024-03-01 | Janssen Research & Development, LLC | ASCENSION SETON | $342 | 70033093ACS3003 | 2024 |
| 2024-02-14 | Janssen Research & Development, LLC | ASCENSION SETON | $1,532 | 70033093ACS3003 | 2024 |
| 2024-02-07 | Amgen Inc. | ASCENSION TEXAS CARDIOVASCULAR KYLE | $19,651 | ACS-REAL Pragmatic study EVOLVE MI | 2024 |
| 2024-01-19 | Janssen Research & Development, LLC | ASCENSION SETON | $3,459 | 70033093ACS3003 | 2024 |
| 2023-12-06 | Janssen Research & Development, LLC | ASCENSION SETON | $2,582 | 70033093ACS3003 | 2023 |
| 2023-12-01 | Janssen Research & Development, LLC | ASCENSION SETON | $496 | 70033093ACS3003 | 2023 |
| 2023-11-20 | Janssen Research & Development, LLC | ASCENSION SETON | $31 | 70033093ACS3003 | 2023 |
| 2023-11-17 | Janssen Research & Development, LLC | ASCENSION SETON | $1,433 | 70033093ACS3003 | 2023 |
| 2023-10-25 | Janssen Research & Development, LLC | ASCENSION SETON | $3,459 | 70033093ACS3003 | 2023 |
| 2023-09-28 | Terumo Medical Corporation | Ascension Seton Medical Center | $50 | OSPREY ILIAC: OCCLUSIVE/STENOTIC PERIPHERAL ARTERY REVASCULARIZATION STUDY FOR COMMON AND/OR EXTERNAL ILIAC ARTERY USING | 2023 |
| 2023-09-18 | Janssen Research & Development, LLC | ASCENSION SETON | $18,200 | 70033093ACS3003 | 2023 |
| 2023-08-23 | Terumo Medical Corporation | Ascension Seton Medical Center | $5,600 | OSPREY ILIAC: OCCLUSIVE/STENOTIC PERIPHERAL ARTERY REVASCULARIZATION STUDY FOR COMMON AND/OR EXTERNAL ILIAC ARTERY USING | 2023 |
| 2023-08-07 | Janssen Research & Development, LLC | ASCENSION SETON | $14,200 | 70033093ACS3003 | 2023 |
| 2023-05-04 | Terumo Medical Corporation | Ascension Seton Medical Center | $13,490 | OSPREY ILIAC: OCCLUSIVE/STENOTIC PERIPHERAL ARTERY REVASCULARIZATION STUDY FOR COMMON AND/OR EXTERNAL ILIAC ARTERY USING | 2023 |
| 2023-05-04 | Terumo Medical Corporation | Ascension Seton Medical Center | $1,200 | OSPREY ILIAC: OCCLUSIVE/STENOTIC PERIPHERAL ARTERY REVASCULARIZATION STUDY FOR COMMON AND/OR EXTERNAL ILIAC ARTERY USING | 2023 |
| 2022-09-09 | Terumo Medical Corporation | Ascension Seton Medical Center | $500 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 |
| 2022-08-12 | Terumo Medical Corporation | Ascension Seton Medical Center | $1,920 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 |
| 2022-08-12 | Terumo Medical Corporation | Ascension Seton Medical Center | $1,076 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 |
| 2022-07-22 | Terumo Medical Corporation | Ascension Seton Medical Center | $1,696 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 |
| 2022-02-04 | Terumo Medical Corporation | Ascension Seton Medical Center | $960 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 |
| 2021-08-15 | Terumo Medical Corporation | Ascension Seton Medical Center | $19,941 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2021 |
| 2021-04-04 | Terumo Medical Corporation | Ascension Seton Medical Center | $6,000 | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kyle, TX, county Hays County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Kyle, TX | County Hays County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 56,823 | 268,638 | 30,188,424 |
| Population, 2020 census P1 | 45,697 | 241,067 | 29,145,505 |
| Median age B01002 | 34.1 | 34.1 | 35.6 |
| Under 18 B01001 | 25.4% | 22.4% | 25.0% |
| 65 and over B01001 | 8.0% | 12.2% | 13.4% |
| Households B11001 | 20,714 | 99,849 | 10,992,816 |
| Foreign born B05002 | 11.3% | 9.8% | 17.6% |
| Median household income B19013 | $90,323 | $89,097 | $78,476 |
| Median family income B19113 | $101,165 | $112,128 | $94,599 |
| Per capita income B19301 | $38,215 | $44,565 | $40,752 |
| Poverty rate B17001 | 8.9% | 12.1% | 13.8% |
| Unemployment rate B23025 | 3.1% | 4.4% | 5.3% |
| Civilian labor force B23025 | 32,781 | 147,110 | 15,233,563 |
| Mean commute (minutes) B08013 | 36.4 | 31.3 | 26.7 |
| Bachelor's degree or higher B15003 | 31.0% | 43.2% | 33.8% |
| Housing units B25001 | 21,218 | 104,675 | 12,128,515 |
| Owner-occupied B25003 | 67.1% | 64.1% | 62.6% |
| Renters B25003 | 32.9% | 35.9% | 37.4% |
| Median home value B25077 | $334,600 | $399,800 | $283,800 |
| Median gross rent B25064 | $1,752 | $1,495 | $1,403 |
| White, not Hispanic B03002 | 38.9% | 50.5% | 39.1% |
| Black B03002 | 4.5% | 3.8% | 11.9% |
| Hispanic or Latino B03002 | 51.8% | 39.4% | 39.7% |
| Asian B03002 | 1.0% | 2.0% | 5.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kyle, TX.
Comments